Study assessing the Use and Safety of Pioglitazone Post Label Change in Denmark: A Post-Authorisation Safety Study (PASS)

Trial Profile

Study assessing the Use and Safety of Pioglitazone Post Label Change in Denmark: A Post-Authorisation Safety Study (PASS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Pioglitazone (Primary) ; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Sep 2017 New trial record
    • 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top